BARCELONA, Spain and CAMBRIDGE, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that the Company will have an oral presentation on ORY-2001, a dual LSD1-MAOB inhibitor, at the 8th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference in Barcelona, Spain.
The oral presentation will be delivered by Dr. Tamara Maes, Oryzon's Co-Founder and Chief Scientific Officer, in Late Breaking Communication on Friday, November 6, 2015 at 12:00pm CET. The title of the presentation is "ORY-2001 An epigenetic drug for the treatment of cognitive defects in Alzheimer's Disease and other neurodegenerative disorders."
Oryzon is advancing its research in neurodegenerative diseases, such as Alzheimer's Disease, Parkinson's Disease and other dementias with the development of ORY-2001. The molecule, which focuses on cognitive decline and memory loss, is expected to begin human clinical trials in early 2016. The drug has demonstrated a good safety profile and therapeutic index in preclinical trials.
Dr. Tamara Maes, Chief Scientific Officer commented, "We are excited to have the opportunity to present on ORY-2001 to world class leaders in that space. Data obtained from preclinical studies of ORY-2001 strongly validate its potential to treat the cognitive defects resulting from neurodegenerative disorders. We look forward to advancing our development of ORY-2001 to address such a challenging and prevalent disease."
The 8th Annual International Conference on Clinical Trials for Alzheimer's Disease will gather more than 800 global researchers to review the most important and promising developments in the field. Clinical trial teams from around the world will report on their efforts to identify new biomarkers, discover more sensitive tools to identify those at risk for the disease and assess the effectiveness of new treatments. This year's meeting will feature over 70 presentations and more than 200 poster sessions on Phase 2 and 3 clinical trials, prevention studies and animal models.
Founded in 2000 in Barcelona, Spain, Oryzon is a privately held, clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with ROCHE. Oryzon's LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one is anticipated to enter clinical trials in early 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has also a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.
CONTACT: Europe IR Contact Ms Anna K Baran IR Director firstname.lastname@example.org +44 (0) 752 1083 006 US IR Contact: The Ruth Group Lee Roth / Tram Bui email@example.com firstname.lastname@example.org (646) 536-7012/7035 Spain PR Contact: Atrevia Ana Melgar / Patricia Cobo email@example.com +34 91 564 07 25Source: Oryzon